drugset
drugset / Trial / NCT04988308

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04988308 ↗

Phase 2 Terminated 151 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).

Timeline

Start
2021-10-12
Primary completion
2022-10-14
Completion
2022-11-23

Outcome

Outcome not reported

Stopped: “Study has been prematurely terminated as the Interim Analysis 1 efficacy results met the prespecified futility criteria related to the primary endpoint.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Bermekimab Monoclonal antibody — Subcutaneous

Indications

hidradenitis suppurativa